Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: General Education DVDOther: Bone Pain Education DVD
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 304
- Registration Number
- NCT01752907
- Locations
- 🇺🇸
Research Site, Burien, Washington, United States
Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 17
- Registration Number
- NCT01744782
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇧🇷Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 217
- Registration Number
- NCT01740297
- Locations
- 🇩🇪
Research Site, Tübingen, Germany
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT01737879
- Locations
- 🇺🇸
Research Site, Chesapeake, Virginia, United States
Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT01733316
- Locations
- 🇫🇷
Hôpital Necker-Enfants Malades, Paris, France
🇧🇪University Hospital of Leuven, Leuven, Belgium
🇺🇸California Pacific Medical Center (CPMC) Research Institute, San Francisco, California, United States
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
Phase 4
Completed
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- Biological: DenosumabDrug: Placebo to Zoledronic AcidDrug: Placebo to Denosumab
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 643
- Registration Number
- NCT01732770
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients
Completed
- Conditions
- Wild-type RAS Metastatic Colorectal Cancer
- Interventions
- Other: Panitumumab + Chemotherapy
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 213
- Registration Number
- NCT01732783
Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT01723514
- Locations
- 🇧🇪
Research Site, Leuven, Belgium
Study to Evaluate the Prospective Payment System
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2248
- Registration Number
- NCT01717989
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
NOLAN: Naproxen or Loratadine and Neulasta
Phase 2
Completed
- Conditions
- Bone Pain in Stage I - III Breast Cancer
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT01712009
- Locations
- 🇺🇸
Research Site, Weston, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath